1-16 of 16
Therese Aurran Schleinitz
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Minimal Residual Disease-Guided Combination of Ibrutinib and Venetoclax Compared to FCR in Untreated Patients with CLL of Intermediate Risk : Final Results of the Eradic Trial from the Filo Group

Anne Sophie Michallet, Remi Letestu, Magali Legarff, Stéphane Morisset, Therese Aurran-Schleinitz, Kamel Laribi, Vincent Levy, Laurence Simon, Damien Roos Weil, Marie Sarah Dilhuydy, Cecile Tomowiak, Caroline Dartigeas, Romain Guieze, Olivier Tournilhac, Emmanuelle Ferrant, Sophie De Guibert, Pierre Feugier, Fatiha Merabet, Stéphane Lepretre, Philippe Carassou, Julie Gay, Benedicte Hivert, Luc-Matthieu Fornecker, Jehan Dupuis, Lysiane Molina, Bruno Villemagne, Guillaume Cartron, Bernard Drenou, Omar Benbrahim, Xavier Cahu, Florence Nguyen Khac, Valerie Rouillé, Loic Ysebaert, Anne Quinquenel
Journal: Blood
Blood (2024) 144 (Supplement 1): 584.
https://doi.org/10.1182/blood-2024-194593
Published: 2024
Journal Articles

Preemptive Therapy with Venetoclax for High-Risk Stage a CLL Patients: First Analysis of Prevene, a Phase II Trial of the Filo Group

Luc-Matthieu Fornecker, Rémi Letestu, Nanthara Shritaran, Emmanuelle Ferrant, Fressia Honeyman, Therese Aurran-Schleinitz, Fatiha Merabet, Pierre Morel, Abderrazak El Yamani, Jehan Dupuis, Kamel Laribi, Stephane Lepretre, Lysiane Molina, Hugo Legendre, Chadi Al Nawakil, Bruno Villemagne, Anne-Sophie Michallet, Béatrice Mahé, Omar Benbrahim, Laurence Sanhes, Caroline Dartigeas, Aline Clavert, Vincent Levy
Journal: Blood
Blood (2024) 144 (Supplement 1): 3256.
https://doi.org/10.1182/blood-2024-203081
Published: 2024
Journal Articles

Lenalidomide Consolidation Improves Measurable Residual Disease (MRD) Rates and Progression Free Survival in Patients with Chronic Lymphocytic Leukemia Following Initial FCR Chemotherapy - Final Analysis of CLL6 Residuum Study of the Australian Leukaemia and Lymphoma Group (ALLG) and the French Innovative Leukemia Organization (FILO)

Therese Aurran-Schleinitz, Stephen P Mulligan, Remi Letestu, Marie Christine Bene, Gavin Cull, Jean Pierre Vilque, Constantine S. Tam, Sophie De Guibert, Rosemary Anne Harrup, Bernard Drenou, Andrew P Grigg, Laurent Voillat, Belinda E Butcher, Caroline Dartigeas, Richard Eek, Nicolas Daguindau, Cecily Forsyth, Mourad Tiab, Delaine Smith, Jennifer Curnow, Veronique Leblond, Stephen Robert Larsen, Florence Cymbalista, David Gottlieb
Journal: Blood
Blood (2023) 142 (Supplement 1): 4641.
https://doi.org/10.1182/blood-2023-181595
Published: 2023
Journal Articles

Combined Treatment with Ibrutinib and Anti-CD38 Monoclonal Antibody Daratumumab in Relapsed/Refractory Chronic Lymphocytic Leukemia with TP53 Aberrations: Results of the Filo Phase II Study IDA53

Therese Aurran-Schleinitz, Cécile Tomowiak, Damien Roos-Weil, Emmanuelle Ferrant, Béatrice Mahé, Lysiane Molina, Loic Ysebaert, Luc Mathieu Fornecker, Anne-Sophie Michallet, Vincent Levy, Romain Guieze, Alain Delmer
Journal: Blood
Blood (2022) 140 (Supplement 1): 7030–7031.
https://doi.org/10.1182/blood-2022-163096
Published: 2022
Journal Articles

A Fixed-Duration Immunochemotherapy Approach Combined with Ibrutinib in CLL Produces Deep and Sustained MRD Responses: 5.5-Year Results from the Icll-07 Filo Trial

Anne-Sophie Michallet, Rémi Letestu, Magali Le Garff-Tavernier, Carmen Aanaei, Michel Ticchioni, Marie-Sarah Dilhuydy, Stephane Morisset, Valérie Rouille, Béatrice Mahé, Kamel Laribi, Bruno Villemagne, Emmanuelle Ferrant, Olivier Tournilhac, Alain Delmer, Christelle Portois, Lysiane Molina, Véronique Leblond, Cécile Tomowiak, Sophie de Guibert, Frederique Orsini, Anne Banos, Philippe Carassou, Guillaume Cartron, Luc Mathieu Fornecker, Loic Ysebaert, Caroline Dartigeas, Margot Truchan, Jean-Pierre Vilque, Therese Aurran Schleinitz, Cymbalista Florence, Stéphane Leprêtre, Vincent Lévy, Florence Nguyen Khac, Pierre Feugier
Journal: Blood
Blood (2022) 140 (Supplement 1): 7013–7015.
https://doi.org/10.1182/blood-2022-157963
Published: 2022
Journal Articles

Preliminary Results of the Filo Phase 2 Trial for Untreated Fit Patients with Intermediate Risk Chronic Lymphocytic Leukemia Comparing Ibrutinib Plus Venetoclax (IV) Versus FCR: Results of the Month 15 MRD Evaluation

Anne Quinquenel, Rémi Letestu, Magali Le Garff-Tavernier, Fabien Subtil, Therese Aurran-Schleinitz, Kamel Laribi, Florence Cymbalista, Vincent Levy, Laurence Simon, Damien Roos-Weil, Véronique Leblond, Marie-Sarah Dilhuydy, Caroline Dartigeas, Cecile Tomowiak, Romain Guieze, Olivier Tournilhac, Emmanuelle Ferrant, Sophie de Guibert, Pierre Feugier, Fatiha Merabet, Stephane Lepretre, Philippe Carassou, Julie Gay, Bénédicte Hivert, Luc Mathieu Fornecker, Jehan Dupuis, Lysiane Molina, Bruno Villemagne, Guillaume Cartron, Bernard Drenou, Béatrice Mahé, Omar Benbrahim, Xavier Cahu, Christelle Portois, Loic Ysebaert, Florence Nguyen Khac, Valérie Rouille, Alain Delmer, Anne-Sophie Michallet
Journal: Blood
Blood (2022) 140 (Supplement 1): 7007–7009.
https://doi.org/10.1182/blood-2022-159678
Published: 2022
Journal Articles

Blinatumomab for Patients with Richter Syndrome: Final Results of the Phase 2 Blinart Trial from the Filo Group

Romain Guieze, Loic Ysebaert, Damien Roos-Weil, Luc-Matthieu Fornecker, Emmanuelle Ferrant, Lysiane Molina, Thérèse Aurran-Schleinitz, Aline Clavert, Sophie de Guibert, Anne-Sophie Michallet, Alain Saad, Bernard Drenou, Philippe Quittet, Benedicte Hivert, Kamel Laribi, Julie Gay, Julien Broséus, Valérie Rouille, David Schwartz, Bruno Pereira, Alain Delmer, Pierre Feugier
Journal: Blood
Blood (2022) 140 (Supplement 1): 6631–6632.
https://doi.org/10.1182/blood-2022-159695
Published: 2022
Journal Articles

Ibrutinib responsive central nervous system involvement in chronic lymphocytic leukemia

Clinical Trials & Observations
Anne Wanquet, Rudy Birsen, Richard Lemal, Mathilde Hunault, Véronique Leblond, Thérèse Aurran-Schleinitz
Journal: Blood
Blood (2016) 127 (19): 2356–2358.
https://doi.org/10.1182/blood-2016-02-697193
Published: 2016
Journal Articles

First Line Chronic Lymphocytic Leukemia Immunochemotherapy for the Elderly Patients over 79 Years Is Feasible, and Achieves Good Results: A Filo Retrospective Study

Godelieve Meunier, Loïc Ysebaert, MD PhD, Phi Linh Nguyen-Thi, MD PhD, Stephane Lepretre, MD, Anne Quinquenel, MD, Jehan Dupuis, MD, Richard Lemal, MD, Therese Aurran-Schleinitz, MD, Cecile Tomowiak, MD, Florence Cymbalista, MD PhD, Marie Sarah Dilhuydy, MD, Annie Brion, MD, Pierre Morel, MD, Bruno Cazin, MD, Veronique Leblond, MD PhD, Guillaume Cartron, MD PhD, Daniel Ré, MD, Marie C Bene, PharmSciD, PhD, Anne-Sophie Michallet, MD, Pierre Feugier, MD PhD
Journal: Blood
Blood (2015) 126 (23): 4170.
https://doi.org/10.1182/blood.V126.23.4170.4170
Published: 2015
Journal Articles

Central Nervous System Involvement in Chronic Lymphocytic Leukemia: Diagnosis and Treatment in a Retrospective Cohort of Thirty Patients

Anne Wanquet, Rudy Birsen, Sylvain Choquet, MD, Vincent Levy, MD PhD, Jehan Dupuis, MD, Stephane Lepretre, MD, Daniel Re, MD, Jonathan Fahri, Mathilde Hunault, MD PhD, Charlotte Bonnet, Anne-Sophie Michallet, MD, Loic Ysebaert, MD PhD, Richard Lemal, MD, Thierry Lamy, MD PhD, Richard Delarue, MD, Atchroue Johnson Ansah, Sylvain P Chantepie, MD, Xavier Troussard, MD PhD, Frederic Davi, Florence Cymbalista, MD PhD, Pierre-Yves Dietrich, Veronique Leblond, MD PhD, Therese Aurran-Schleinitz, MD
Journal: Blood
Blood (2015) 126 (23): 2948.
https://doi.org/10.1182/blood.V126.23.2948.2948
Published: 2015
Journal Articles

Bendamustine, Ofatumumab and High-Dose Methylprednisolone (BOMP) in Relapsed/Refractory CLL: Results of a Planned Interim Analysis of the French CLL Intergroup ICLL01 Phase II Trial

Sophie de Guibert, MD, Marie-Sarah Dilhuydy, MD, Loic Ysebaert, Laurence Sanhès, MD, Sylvain Choquet, MD, Therese Aurran-Schleinitz, MD, Romain Guieze, MD, Beatrice Mahe, MD, Nicolas Daguindau, MD, Carla Araujo, MD, Hussam Saad, MD, Emmanuelle Ferrant, MD, Bruno Cazin, MD, Pierre Feugier, MD PhD, Brigitte Dreyfus, MD, Delmer Alain, MD, Stéphane Lepretre, MD, Magali Le Garff-Tavernier, PharmD, PhD, Véronese Lauren, MD, Anna Schuh, MDPhD, Bruno Pereira, Veronique Leblond, MD PhD, Olivier Tournilhac, MD
Journal: Blood
Blood (2014) 124 (21): 3341.
https://doi.org/10.1182/blood.V124.21.3341.3341
Published: 2014
Journal Articles

Role Of Allogeneic Transplant In Poor Risk CLL Patients: A Long-Term Monocentric Experience In 39 Patients

Therese Aurran-Schleinitz, MD, Anne Wanquet, Sabine Furst, MD, Benjamin Esterni, Ph.D., Reda Bouabdallah, MD, Diane Coso, MD, Christine Arnoulet, Pharm. D., Jean El Cheikh, MD, Catherine Faucher, MD, Luca Castagna, MD, Christian Chabannon, MD, PhD, Didier Blaise
Journal: Blood
Blood (2013) 122 (21): 5531.
https://doi.org/10.1182/blood.V122.21.5531.5531
Published: 2013
Journal Articles

TP53 Mutation or Deletion and Efficacy with Single-Agent Lenalidomide in Relapsed or Refractory Chronic Lymphocytic Leukemia (CLL) (CC-5013-CLL-009 Study)

Andreas Bühler, Clemens Wendtner, MD, Michael Hallek, Thomas J. Kipps, MD, PhD, Laura Rassenti, PhD, Graeme Fraser, Anne-Sophie Michallet, Peter Hillmen, Jan Duerig, MD, Stephanie A. Gregory, Matt Kalaycio, MD, Therese Aurran-Schleinitz, Livio Trentin, Brendan Purse, Jennie Zhang, Jay Mei, MD, Stephan Stilgenbauer, MD
Journal: Blood
Blood (2013) 122 (21): 1638.
https://doi.org/10.1182/blood.V122.21.1638.1638
Published: 2013
Journal Articles

Salvage Therapies in Patients with High-Risk Relapse After Fludarabine, Cyclophosphamide, Rituximab (FCR) for Chronic Lymphocytic Leukemia: The French CLL Intergroup Experience

Luc-Matthieu Fornecker, MD, Therese Aurran-Schleinitz, Anne-Sophie Michallet, MD, PhD, Bruno Cazin, MD, Jehan Dupuis, MD, Romain Guieze, MD, Marie-Sarah Dilhuydy, MD, Jean-Marc Zini, MD, PhD, Cécile Tomowiak, MD, Stéphane Leprêtre, MD, Florence Cymbalista, MD, PhD, Annie Brion, MD, Pierre Feugier, MD, PhD, Veronique Leblond, Loic Ysebaert, MD PhD
Journal: Blood
Blood (2012) 120 (21): 1796.
https://doi.org/10.1182/blood.V120.21.1796.1796
Published: 2012
Journal Articles

Potential Synergic Effect of Lenalidomide-Rituximab Combination: Durable Complete Remissions in Refractory Diffuse Large B Cell Lymphoma

Vadim Ivanov, MD, PhD, Diane Coso, MD, Therese Aurran-Schleinitz, MD, Jean-Marc Schiano de Colella, MD, Anne-Marie Stoppa, MD, Jerome Rey, MD, Florence Broussais, MD, Didier Blaise, MD, Reda Bouabdallah, MD
Journal: Blood
Blood (2011) 118 (21): 4989.
https://doi.org/10.1182/blood.V118.21.4989.4989
Published: 2011
Journal Articles

Frontline High Dose Chemotherapy Supported by Autologous PBSCT Might Improve Survival In Elderly Patients (≥60 Years) with High Risk Diffuse Large B-Cell Lymphoma (DLBCL)

Vadim Ivanov, MD, Diane Coso, MD, Jerome Rey, MD, Therese Aurran-Schleinitz, MD, Anne-Marie Stoppa, MD, Jean-Marc Schiano de Colella, MD, Didier Blaise, MD, Reda Bouabdallah, MD
Journal: Blood
Blood (2010) 116 (21): 5190.
https://doi.org/10.1182/blood.V116.21.5190.5190
Published: 2010